Xponance Inc. Reduces Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Xponance Inc. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 0.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,770 shares of the company’s stock after selling 414 shares during the quarter. Xponance Inc.’s holdings in Moderna were worth $1,862,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA. State Street Corp lifted its stake in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Wellington Management Group LLP raised its holdings in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Amundi raised its holdings in Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company’s stock worth $52,075,000 after purchasing an additional 535,273 shares in the last quarter. Two Sigma Advisers LP bought a new position in Moderna in the third quarter worth $23,825,000. Finally, Douglas Lane & Associates LLC raised its holdings in Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MRNA shares. Morgan Stanley decreased their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. reduced their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $59.00.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $32.66 on Friday. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The business has a 50-day simple moving average of $34.91 and a two-hundred day simple moving average of $45.86. The firm has a market cap of $12.60 billion, a price-to-earnings ratio of -3.52 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.